Serum vaspin and adiponectin levels in patients with prolactinoma

References

• Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev 2000;80:1523–631.
   PubMed Web of Science ®Google Scholar
• De Assuncao Alves Rodrigues LF, Campos SM, Miranda PA, Bizzi MF, Sales Do Amaral PH, Giannetti AV, Ribeiro-Oliveira A. Prolactinoma: a condition associated with hypoadiponectinemia. Horm Metab Res 2012;44: 832–8.
   PubMed Web of Science ®Google Scholar
• Nilsson L, Binart N, Bohlooly YM, Bramnert M, Egecioglu E, Kindblom J, Kelly PA, Kopchick JJ, Ormandy CJ, Ling C, Billig H. Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue. Biochem Biophys Res Commun 2005;331:1120–6.
   PubMed Web of Science ®Google Scholar
• Schlechte JA. Clinical practice. Prolactinoma. N Engl J Med 2003;349:2035–41.
   PubMed Web of Science ®Google Scholar
• Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD, Faggiano A, Biondi B, Lombardi G. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 2003;148:325–31.
   PubMed Web of Science ®Google Scholar
• Berinder K, Nystrom T, Hoybye C, Hall K, Hulting AL. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary 2011;14:199–207.
   PubMed Web of Science ®Google Scholar
• Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930–5.
   PubMed Web of Science ®Google Scholar
• Asai-Sato M, Okamoto M, Endo M, Yoshida H, Murase M, Ikeda M, Sakakibara H, Takahashi T, Hirahara F. Hypoadiponectinemia in lean lactating women: prolactin inhibits adiponectin secretion from human adipocytes. Endocr J 2006;53:555–62.
   PubMed Web of Science ®Google Scholar
• Fuglsang J, Skjaerbaek C, Frystyk J, Flyvbjerg A, Ovesen P. A longitudinal study of serum adiponectin during normal pregnancy. BJOG 2006;113:110–13.
   PubMed Web of Science ®Google Scholar
• Ko BJ, Lee M, Park HS, Han K, Cho GJ, Hwang TG, Kim JH, Lee SH, Lee HY, Kim SM. Elevated vaspin and leptin levels are associated with obesity in prepubertal Korean children. Endocr J 2013;60:609–16.
   PubMed Web of Science ®Google Scholar
• Choi SH, Hong ES, Lim S. Clinical implications of adipocytokines and newly emerging metabolic factors with relation to insulin resistance and cardiovascular health. Front Endocrinol (Lausanne) 2013;4:97.
   PubMedGoogle Scholar
• Youn BS, Kloting N, Kratzsch J, Lee N, Park JW, Song ES, Ruschke K, Oberbach A, Fasshauer M, Stumvoll M, Bluher M. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008;57:372–7.
   PubMed Web of Science ®Google Scholar
• Suleymanoglu S, Tascilar E, Pirgon O, Tapan S, Meral C, Abaci A. Vaspin and its correlation with insulin sensitivity indices in obese children. Diabetes Res Clin Pract 2009;84:325–8.
   PubMed Web of Science ®Google Scholar
• Choi SH, Kwak SH, Lee Y, Moon MK, Lim S, Park YJ, Jang HC, Kim MS. Plasma vaspin concentrations are elevated in metabolic syndrome in men and are correlated with coronary atherosclerosis in women. Clin Endocrinol (Oxf) 2011;75:628–35.
   PubMed Web of Science ®Google Scholar
• Auguet T, Quintero Y, Riesco D, Morancho B, Terra X, Crescenti A, Broch M, Aguilar C, Olona M, Porras JA, Hernandez M, Sabench F, Del Castillo D, Richart C. New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese women. BMC Med Genet 2011;12:60.
   PubMed Web of Science ®Google Scholar
• Martos-Moreno GA, Kratzsch J, Korner A, Barrios V, Hawkins F, Kiess W, Argente J. Serum visfatin and vaspin levels in prepubertal children: effect of obesity and weight loss after behavior modifications on their secretion and relationship with glucose metabolism. Int J Obes (Lond) 2011;35:1355–62.
   PubMed Web of Science ®Google Scholar
• Cinar N, Gurlek A. Association between novel adipocytokines adiponectin, vaspin, visfatin, and thyroid: an experimental and clinical update. Endocr Connect 2013;2:R30–8.
   PubMed Web of Science ®Google Scholar
• Defronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173–94.
   PubMed Web of Science ®Google Scholar
• Kloting N, Berndt J, Kralisch S, Kovacs P, Fasshauer M, Schon MR, Stumvoll M, Bluher M. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 2006;339:430–6.
   PubMed Web of Science ®Google Scholar
• Li Q, Chen R, Moriya J, Yamakawa J, Sumino H, Kanda T, Takahashi T. A novel adipocytokine, visceral adipose tissue-derived serine protease inhibitor (vaspin), and obesity. J Int Med Res 2008;36:625–9.
   PubMed Web of Science ®Google Scholar
• Ye Y, Hou XH, Pan XP, Lu JX, Jia WP. Serum vaspin level in relation to postprandial plasma glucose concentration in subjects with diabetes. Chin Med J (Engl) 2009;122: 2530–3.
   PubMed Web of Science ®Google Scholar
• Kempf K, Rose B, Illig T, Rathmann W, Strassburger K, Thorand B, Meisinger C, Wichmann HE, Herder C, Vollmert C. Vaspin (SERPINA12) genotypes and risk of type 2 diabetes: results from the MONICA/KORA studies. Exp Clin Endocrinol Diabetes 2010;118:184–9.
   PubMed Web of Science ®Google Scholar
• Von Loeffelholz C, Mohlig M, Arafat AM, Isken F, Spranger J, Mai K, Randeva HS, Pfeiffer AF, Weickert MO. Circulating vaspin is unrelated to insulin sensitivity in a cohort of nondiabetic humans. Eur J Endocrinol 2010;162:507–13.
   PubMed Web of Science ®Google Scholar
• Olarescu NC, Heck A, Godang K, Ueland T, Bollerslev J. The metabolic risk in newly diagnosed patients with acromegaly is related to fat distribution and circulating adipokines and improves after treatment. Neuroendocrinology 2015.
   PubMedGoogle Scholar
• Goktas Z, Owens S, Boylan M, Syn D, Shen CL, Reed DB, San Francisco S, Wang S. Associations between tissue visfatin/nicotinamide, phosphoribosyltransferase (nampt), retinol binding protein-4, and vaspin concentrations and insulin resistance in morbidly obese subjects. Mediators Inflamm 2013;2013:861496.
   PubMed Web of Science ®Google Scholar
• Zinger M, Mcfarland M, Ben-Jonathan N. Prolactin expression and secretion by human breast glandular and adipose tissue explants. J Clin Endocrinol Metab 2003;88:689–96.
   PubMed Web of Science ®Google Scholar
• Ling C, Svensson L, Oden B, Weijdegard B, Eden B, Eden S, Billig H. Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J Clin Endocrinol Metab 2003;88:1804–8.
   PubMed Web of Science ®Google Scholar
• Flint DJ, Binart N, Kopchick J, Kelly P. Effects of growth hormone and prolactin on adipose tissue development and function. Pituitary 2003;6:97–102.
   PubMedGoogle Scholar
• Atmaca A, Bilgici B, Ecemis GC, Tuncel OK. Evaluation of body weight, insulin resistance, leptin and adiponectin levels in premenopausal women with hyperprolactinemia. Endocrine 2013;44:756–61.
   PubMed Web of Science ®Google Scholar
• Combs TP, Berg AH, Rajala MW, Klebanov S, Iyengar P, Jimenez-Chillaron JC, Patti ME, Klein SL, Weinstein RS, Scherer PE. Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes 2003;52:268–76.
   PubMed Web of Science ®Google Scholar
• Creemers LB, Zelissen PM, Van’T Verlaat JW, Koppeschaar HP. Prolactinoma and body weight: a retrospective study. Acta Endocrinol (Copenh) 1991;125:392–6.
   PubMedGoogle Scholar
• Doknic M, Pekic S, Zarkovic M, Medic-Stojanoska M, Dieguez C, Casanueva F, Popovic V. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol 2002;147:77–84.
   PubMed Web of Science ®Google Scholar
• Shibli-Rahhal A, Schlechte J. The effects of hyperprolactinemia on bone and fat. Pituitary 2009;12:96–104.
   PubMed Web of Science ®Google Scholar
• Dos Santos Silva CM, Barbosa FR, Lima GA, Warszawski L, Fontes R, Domingues RC, Gadelha MR. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring) 2011;19:800–5.
   PubMed Web of Science ®Google Scholar
• Landgraf R, Landraf-Leurs MM, Weissmann A, Horl R, Von Werder K, Scriba PC. Prolactin: a diabetogenic hormone. Diabetologia 1977;13:99–104.
   PubMed Web of Science ®Google Scholar
• Tuzcu A, Bahceci M, Dursun M, Turgut C, Bahceci S. Insulin sensitivity and hyperprolactinemia. J Endocrinol Invest 2003;26:341–6.
   PubMed Web of Science ®Google Scholar
• Serri O, Li L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G. The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf) 2006;64:366–70.
   PubMed Web of Science ®Google Scholar
• Inancli SS, Usluogullari A, Ustu Y, Caner S, Tam AA, Ersoy R, Cakir B. Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma. Endocrine 2013;44:193–9.
   PubMed Web of Science ®Google Scholar
• Defronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214–23.
   PubMed Web of Science ®Google Scholar
• Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487–95.
   PubMed Web of Science ®Google Scholar
• Tuzcu A, Yalaki S, Arikan S, Gokalp D, Bahcec M, Tuzcu S. Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique. Pituitary 2009;12:330–4.
   PubMed Web of Science ®Google Scholar
• Galsgaard ED, Nielsen JH, Moldrup A. Regulation of prolactin receptor (PRLR) gene expression in insulin-producing cells. Prolactin and growth hormone activate one of the rat prlr gene promoters via STAT5a and STAT5b. J Biol Chem 1999;274:18686–92.
   PubMed Web of Science ®Google Scholar
• Cejkova P, Fojtikova M, Cerna M. Immunomodulatory role of prolactin in diabetes development. Autoimmun Rev 2009;9:23–7.
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Prager R, Punzengruber C, Luger A. Severe hyperprolactinaemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia 1985;28:138–42.
   PubMed Web of Science ®Google Scholar
• Park S, Kim Da S, Daily JW, Kim SH. Serum prolactin concentrations determine whether they improve or impair beta-cell function and insulin sensitivity in diabetic rats. Diabetes Metab Res Rev 2011;27:564–74.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–19.
   PubMed Web of Science ®Google Scholar
• Stofkova A. Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity. Endocr Regul 2010;44:25–36.
   PubMedGoogle Scholar
• Toruner F, Altinova AE, Akturk M, Kaya M, Arslan E, Bukan N, Kan E, Yetkin I, Arslan M. The relationship between adipocyte fatty acid binding protein-4, retinol binding protein-4 levels and early diabetic nephropathy in patients with type 2 diabetes. Diabetes Res Clin Pract 2011;91:203–7.
   PubMed Web of Science ®Google Scholar
• Hattori Y, Hattori S, Akimoto K, Nishikimi T, Suzuki K, Matsuoka H, Kasai K. Globular adiponectin activates nuclear factor-kappaB and activating protein-1 and enhances angiotensin II-induced proliferation in cardiac fibroblasts. Diabetes 2007;56:804–8.
   PubMed Web of Science ®Google Scholar
• Almeda-Valdes P, Cuevas-Ramos D, Mehta R, Gomez-Perez FJ, Cruz-Bautista I, Arellano-Campos O, Navarrete-Lopez M, Aguilar-Salinas CA. Total and high molecular weight adiponectin have similar utility for the identification of insulin resistance. Cardiovasc Diabetol 2010;9:26.
   PubMed Web of Science ®Google Scholar